Indeed, Craig Jordan’s lab showed that primitive CD34+/CD38−/CD123+ AML cells aberrantly express active NF-κB, and that in vitro cell treatment with proteasome inhibitors is sufficient to induce rapid cell death. This evidence concerns the gene NFKB1 and acute myeloid leukemia.